The Boehringer Ingelheim corporation is headquartered in Ingelheim, Germany. Boehringer Ingelheim International GmbH is a global business present in more than sixty nations. The company manufactures and markets human pharmaceuticals (prescription medicines, consumer healthcare products) and products for industrial customers (e.g. chemicals and biopharmaceuticals) and animal health.

Boehringer Ingelheim International GmbH is committed to the research and development of novel antiretroviral agents. Viramune® (nevirapine) is a product of original research done at Boehringer Ingelheim International GmbH. Viramune® was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti- HIV drugs.

Boehringer Ingelheim International GmbH is committed to the rapid development of the investigational non-peptidic protease inhibitor (NPPI) tipranavir in phase III clinical trials, and acquired the nucleoside analogue (NRTI) MIV-310 currently under development. The company is involved in basic research and is committed to improving HIV therapy by providing physicians and patients with innovative antiretrovirals.

For more information on Boehringer Ingelheim International GmbH, please see www.boehringer-ingelheim.com/hiv.